Related Experiment Video

Updated: Apr 15, 2026

Estrogen-Like Effect of Bazi Bushen Capsule in Ovariectomized Rats
08:56

Estrogen-Like Effect of Bazi Bushen Capsule in Ovariectomized Rats

Published on: April 7, 2023

1.5K

Resveratrol prevents osteoporosis in ovariectomized rats by regulating microRNA-338-3p

Da-Wei Guo1, Ya-Xin Han1, Lin Cong1

  • 1Department of Orthopaedics, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China.

Molecular Medicine Reports
|April 8, 2015
PubMed

Insights

Resveratrol (RESV) treatment for osteoporosis was studied in rats. RESV suppresses microRNA-338-3p (miR-338-3p), increasing runt-related transcription factor 2 expression in bone cells.

Area of Science:

  • Biomedical Science
  • Molecular Biology
  • Pharmacology

Background:

  • Osteoporosis is a bone disease marked by decreased bone mass and microstructural degeneration.
  • Resveratrol (RESV) is a compound with potential anti-aging properties that may impact age-related diseases.

Purpose of the Study:

  • To investigate the mechanism of Resveratrol's effect on osteoporosis.
  • To identify microRNAs (miRNAs) affected by RESV treatment in an osteoporosis model.
  • To confirm the role of a specific miRNA in osteoblast function.

Main Methods:

  • An ovariectomized rat model was used to simulate osteoporosis.
  • MicroRNA expression changes were analyzed after RESV treatment.
  • TargetScan software predicted miRNA targets, validated by dual-luciferase reporter assays.
  • The function of miR-338-3p in human osteoblast (HOB) cell proliferation and differentiation was assessed.

Main Results:

  • RESV treatment was found to suppress miR-338-3p expression.
  • This suppression led to an increased expression of runt-related transcription factor 2 (RUNX2) in HOB cells.
  • An intact mechanism for RESV's therapeutic effect in osteoporosis was identified.

Conclusions:

  • Resveratrol exerts a therapeutic effect in osteoporosis by modulating miRNA expression.
  • The study elucidates a molecular pathway involving miR-338-3p and RUNX2 in RESV-treated osteoblasts.
  • This finding provides a basis for developing RESV-based osteoporosis treatments.

More Related Videos

The Creation of a Rat Model for Osteosarcopenia via Ovariectomy03:52

The Creation of a Rat Model for Osteosarcopenia via Ovariectomy

Published on: February 21, 2025

1.5K
Author Spotlight: Integrating Traditional Chinese Medicine with Modern Pharmacology and Genomics for Assessing Postmenopausal Osteoporosis in Mice07:20

Author Spotlight: Integrating Traditional Chinese Medicine with Modern Pharmacology and Genomics for Assessing Postmenopausal Osteoporosis in Mice

Published on: August 23, 2024

1.2K

Related Concept Videos

Osteoclasts in Bone Remodeling01:31

Osteoclasts in Bone Remodeling

Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during...
4.9K
Bone Remodeling01:40

Bone Remodeling

Bone remodeling is a continuous and balanced process of bone resorption by osteoclasts and bone formation by osteoblasts. In adults, it helps maintain bone mass and calcium homeostasis. While mechanical stress can stimulate turnover as part of the normal maintenance and reparative process, several hormones also regulate bone remodeling.
41.3K